Newcomer scores double win

Swedish rare immunological disease specialist Hansa Biopharma has not only registered its first drug in Australia but it has also received the broadest indication yet for the treatment.

The TGA has provisionally approved the company's lead product Idefirix as a desensitisation treatment for highly sensitised patients prior to kidney transplantation from a donor with whom there is a positive cross-match.

This indication allows transplant from either living or deceased donor kidneys whereas the EMA has only conditionally approved the drug for transplant from deceased donor kidneys.